OBJECTIVE: We here describe treatment outcomes in two adenosine deaminase (ADA)-deficiency patients (pt) who received stem cell gene therapy (SCGT) with no cytoreductive conditioning. As this protocol has features distinct from those of other clinical trials, its results provide insights into SCGT for ADA deficiency. PATIENTS AND METHODS: Pt 1 was treated at age 4.7 years, whereas pt 2, who had previously received T-cell gene therapy, was treated at age 13 years. Bone marrow CD34(+) cells were harvested after enzyme replacement therapy (ERT) was withdrawn; following transduction of ADA cDNA by the γ-retroviral vector GCsapM-ADA, they were administered intravenously. No cytoreductive conditioning, at present considered critical for therapeutic benefit, was given before cell infusion. Hematological/immunological reconstitution kinetics, levels of systemic detoxification, gene-marking levels, and proviral insertion sites in hematopoietic cells were assessed. RESULTS: Treatment was well tolerated, and no serious adverse events were observed. Engraftment of gene-modified repopulating cells was evidenced by the appearance and maintenance of peripheral lymphocytes expressing functional ADA. Systemic detoxification was moderately achieved, allowing temporary discontinuation of ERT for 6 and 10 years in pt 1 and pt 2, respectively. Recovery of immunity remained partial, with lymphocyte counts in pts 1 and 2, peaked at 408/mm(3) and 1248/mm(3), approximately 2 and 5 years after SCGT. Vector integration site analyses confirmed that hematopoiesis was reconstituted with a limited number of clones, some of which were shown to have myelo-lymphoid potential. CONCLUSIONS: Outcomes in SCGT for ADA-SCID are described in the context of a unique protocol, which used neither ERT nor cytoreductive conditioning. Although proven safe, immune reconstitution was partial and temporary. Our results reiterate the importance of cytoreductive conditioning to ensure greater benefits from SCGT.
OBJECTIVE: We here describe treatment outcomes in two adenosine deaminase (ADA)-deficiencypatients (pt) who received stem cell gene therapy (SCGT) with no cytoreductive conditioning. As this protocol has features distinct from those of other clinical trials, its results provide insights into SCGT for ADA deficiency. PATIENTS AND METHODS: Pt 1 was treated at age 4.7 years, whereas pt 2, who had previously received T-cell gene therapy, was treated at age 13 years. Bone marrow CD34(+) cells were harvested after enzyme replacement therapy (ERT) was withdrawn; following transduction of ADA cDNA by the γ-retroviral vector GCsapM-ADA, they were administered intravenously. No cytoreductive conditioning, at present considered critical for therapeutic benefit, was given before cell infusion. Hematological/immunological reconstitution kinetics, levels of systemic detoxification, gene-marking levels, and proviral insertion sites in hematopoietic cells were assessed. RESULTS: Treatment was well tolerated, and no serious adverse events were observed. Engraftment of gene-modified repopulating cells was evidenced by the appearance and maintenance of peripheral lymphocytes expressing functional ADA. Systemic detoxification was moderately achieved, allowing temporary discontinuation of ERT for 6 and 10 years in pt 1 and pt 2, respectively. Recovery of immunity remained partial, with lymphocyte counts in pts 1 and 2, peaked at 408/mm(3) and 1248/mm(3), approximately 2 and 5 years after SCGT. Vector integration site analyses confirmed that hematopoiesis was reconstituted with a limited number of clones, some of which were shown to have myelo-lymphoid potential. CONCLUSIONS: Outcomes in SCGT for ADA-SCID are described in the context of a unique protocol, which used neither ERT nor cytoreductive conditioning. Although proven safe, immune reconstitution was partial and temporary. Our results reiterate the importance of cytoreductive conditioning to ensure greater benefits from SCGT.
Authors: Belinda Chan; Diane Wara; John Bastian; Michael S Hershfield; John Bohnsack; Colleen G Azen; Robertson Parkman; Kenneth Weinberg; Donald B Kohn Journal: Clin Immunol Date: 2005-08-22 Impact factor: 3.969
Authors: Barbara C Engel; Greg M Podsakoff; Joanna L Ireland; E Monika Smogorzewska; Denise A Carbonaro; Kathy Wilson; Ami Shah; Neena Kapoor; Mirna Sweeney; Mark Borchert; Gay M Crooks; Kenneth I Weinberg; Robertson Parkman; Howard M Rosenblatt; Shi-Qi Wu; Michael S Hershfield; Fabio Candotti; Donald B Kohn Journal: Blood Date: 2006-09-14 Impact factor: 22.113
Authors: T Ariga; N Oda; K Yamaguchi; N Kawamura; H Kikuta; S Taniuchi; Y Kobayashi; K Terada; H Ikeda; M S Hershfield; K Kobayashi; Y Sakiyama Journal: Blood Date: 2001-05-01 Impact factor: 22.113
Authors: M Onodera; T Ariga; N Kawamura; I Kobayashi; M Ohtsu; M Yamada; A Tame; H Furuta; M Okano; S Matsumoto; H Kotani; G J McGarrity; R M Blaese; Y Sakiyama Journal: Blood Date: 1998-01-01 Impact factor: 22.113
Authors: H Bobby Gaspar; Alessandro Aiuti; Fulvio Porta; Fabio Candotti; Michael S Hershfield; Luigi D Notarangelo Journal: Blood Date: 2009-07-28 Impact factor: 22.113
Authors: Javier Chinen; Joie Davis; Suk See De Ravin; Beverly N Hay; Amy P Hsu; Gilda F Linton; Nora Naumann; Effie Y H Nomicos; Christopher Silvin; Jean Ulrick; Narda L Whiting-Theobald; Harry L Malech; Jennifer M Puck Journal: Blood Date: 2007-03-16 Impact factor: 22.113
Authors: H Bobby Gaspar; Samantha Cooray; Kimberly C Gilmour; Kathryn L Parsley; Stuart Adams; Steven J Howe; Abdulaziz Al Ghonaium; Jinhua Bayford; Lucinda Brown; E Graham Davies; Christine Kinnon; Adrian J Thrasher Journal: Sci Transl Med Date: 2011-08-24 Impact factor: 17.956
Authors: Aaron R Cooper; Georgia R Lill; Kit Shaw; Denise A Carbonaro-Sarracino; Alejandra Davila; Robert Sokolic; Fabio Candotti; Matteo Pellegrini; Donald B Kohn Journal: Blood Date: 2017-03-28 Impact factor: 22.113
Authors: Sandeep Rp Kumar; David M Markusic; Moanaro Biswas; Katherine A High; Roland W Herzog Journal: Mol Ther Methods Clin Dev Date: 2016-05-25 Impact factor: 6.698